LLY

1,009.16

-0.69%↓

JNJ

230.44

+0.55%↑

ABBV

212.88

-0.06%↓

UNH

382.34

-2.4%↓

AZN

188.1

+1.47%↑

LLY

1,009.16

-0.69%↓

JNJ

230.44

+0.55%↑

ABBV

212.88

-0.06%↓

UNH

382.34

-2.4%↓

AZN

188.1

+1.47%↑

LLY

1,009.16

-0.69%↓

JNJ

230.44

+0.55%↑

ABBV

212.88

-0.06%↓

UNH

382.34

-2.4%↓

AZN

188.1

+1.47%↑

LLY

1,009.16

-0.69%↓

JNJ

230.44

+0.55%↑

ABBV

212.88

-0.06%↓

UNH

382.34

-2.4%↓

AZN

188.1

+1.47%↑

LLY

1,009.16

-0.69%↓

JNJ

230.44

+0.55%↑

ABBV

212.88

-0.06%↓

UNH

382.34

-2.4%↓

AZN

188.1

+1.47%↑

Inicio・Lista de Acciones・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Abierto

SectorSanidad

11.8 -0.59

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

11.28

Máximo

12.01

Métricas clave
By Trading Economics
Ingresos	227M
Ventas	139M
P/B Media del Sector	4.506 49.701
Margen de beneficios	163.843
Empleados	1,796
EBITDA	1.3M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+67.36% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	2.1B
Apertura anterior	12.39
Cierre anterior	11.8

Noticias sobre sentimiento de mercado

By Acuity

10%

90%

8 / 345 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

14.24 / 14.78 Soporte y Resistencia

Hutchison China MediTech Ltd ADR Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

19 may 2026, 20:36 UTC

Adquisiciones, fusiones, absorciones

Analog Devices to Buy Empower Semiconductor for $1.5 Billion

19 may 2026, 23:47 UTC

Charlas de Mercado

Nikkei May Decline as Concerns About Energy, Material Costs Persists -- Market Talk

19 may 2026, 23:34 UTC

Charlas de Mercado

Gold Edges Higher on Possible Technical Recovery -- Market Talk

19 may 2026, 23:28 UTC

Charlas de Mercado

Ganancias

Global Forex and Fixed Income Roundup: Market Talk

19 may 2026, 23:28 UTC

Charlas de Mercado

Ganancias

F&P Healthcare's Outlook Key for Investors -- Market Talk

19 may 2026, 23:10 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

19 may 2026, 23:10 UTC

Charlas de Mercado

Kiwi Property's Dividend Growth Reliant on Several Factors -- Market Talk

19 may 2026, 22:02 UTC

Ganancias

ZTO Express (Cayman): Di Xu to Resign From Board

19 may 2026, 22:01 UTC

Ganancias

ZTO Express (Cayman) 1Q Adj EPS 43c >ZTO

19 may 2026, 22:01 UTC

Ganancias

ZTO Express (Cayman) 1Q EPS 39c >ZTO

19 may 2026, 22:00 UTC

Ganancias

ZTO Express (Cayman) 1Q Rev $1.93B >ZTO

19 may 2026, 21:37 UTC

Ganancias

Cracks Are Starting to Appear in the Chip Stock Rally -- Barrons.com

19 may 2026, 21:31 UTC

Adquisiciones, fusiones, absorciones

How NextEra Can Fix Dominion's Strange AI Problem -- Barrons.com

19 may 2026, 21:01 UTC

Ganancias

Home Depot Beats Earnings Estimates as Shoppers Defy Inflation Fears. The Stock Advances. -- Barrons.com

19 may 2026, 20:58 UTC

Ganancias

These Stocks Are Today's Movers: CoreWeave, Nvidia, Home Depot, Akamai, Agilysys, Micron, and More -- Barrons.com

19 may 2026, 20:46 UTC

Acciones populares

Stocks to Watch Recap: ServiceNow, Home Depot, CoreWeave -- WSJ

19 may 2026, 20:43 UTC

Charlas de Mercado

Canada 30-Year Yield Hits Highest Level Since 2010 -- Market Talk

19 may 2026, 20:34 UTC

Ganancias

James Hardie Industries Sees FY27 Sales $5.25B-$5.41B >JHX

19 may 2026, 20:32 UTC

Ganancias

James Hardie Industries: Targeting Pro Forma Adjusted EBITDA Growth of 4% to 8% in FY27 >JHX

19 may 2026, 20:32 UTC

Ganancias

James Hardie Industries 4Q EPS 5c >JHX

19 may 2026, 20:32 UTC

Ganancias

James Hardie Industries 4Q Sales $1.4B >JHX

19 may 2026, 20:21 UTC

Adquisiciones, fusiones, absorciones

Analog Devices to Buy Empower Semiconductor for $1.5B

19 may 2026, 20:18 UTC

Charlas de Mercado

Canada CPI Data Has Accounting Quirk Related to Travel Tours -- Market Talk

19 may 2026, 20:13 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

19 may 2026, 20:13 UTC

Charlas de Mercado

'Hard to Square' Canada Rate Hikes Expectations Given Mild Core -- Market Talk

19 may 2026, 20:03 UTC

Adquisiciones, fusiones, absorciones

Analog Devices: Deal Further Advances Position as Strategic, System-Level Grid-To-Core Power Partner for Hyperscalers, AI Silicon Developers >ADI

19 may 2026, 20:03 UTC

Adquisiciones, fusiones, absorciones

Analog Devices: Phillips Will Continue Leading IVR Technology Efforts as Part of ADI >ADI

19 may 2026, 20:02 UTC

Adquisiciones, fusiones, absorciones

Analog Devices Will Acquire Empower in All-Cash Transaction for $1.5 B >ADI

19 may 2026, 20:02 UTC

Adquisiciones, fusiones, absorciones

Analog Devices to Acquire Empower Semiconductor, Expanding Its Next-Generation High-Density Power Portfolio for the AI Era

19 may 2026, 19:23 UTC

Charlas de Mercado

Oil Futures Slip With Market Back on U.S.-Iran Deal Watch -- Market Talk

Comparación entre iguales

Cambio de precio

Hutchison China MediTech Ltd ADR previsión

Precio Objetivo

By TipRanks

67.36% repunte

Estimación a 12 Meses

Media 20 USD 67.36%

Máximo 20 USD

Mínimo 20 USD

De acuerdo con 1 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Hutchison China MediTech Ltd ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

1 ratings

Comprar

Mantener

Vender

De acuerdo con 1 analistas que ofrecen calificaciones bursátiles a para Hutchison China MediTech Ltd ADR Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

14.24 / 14.78Soporte y Resistencia

Recent bearish events outweigh bullish events.

All events are bearish.

Sentimiento

By Acuity

8 / 345 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.